Episode 141: From Bench Science to Biotech Investment and Venture Funding
What does it take to move from the lab bench to the venture side of biotech, and what are investors looking for in the next generation of breakthrough companies?
In this episode, Elaine Hamm, PhD, sits down with Kevin White, PhD, Executive Director of the Boehringer Ingelheim Venture Fund, to discuss his journey from academic science to pharmaceutical R&D and ultimately to venture investing. Kevin shares how his scientific background shapes his investment philosophy, what it’s like joining one of biotech’s leading corporate venture funds, and the therapeutic areas he believes will define the future of healthcare. Along the way, he offers candid advice for founders navigating today’s investment landscape and explains why curiosity, adaptability, and a willingness to embrace discomfort are essential for success.
In this episode, you’ll discover:
- Why being uncomfortable can be one of the best catalysts for growth.
- How the Boehringer Ingelheim Venture Fund approaches investing, from exploring “white space” opportunities to supporting innovations aligned with the company’s therapeutic priorities.
- Why emerging areas such as women’s health, targeted drug delivery, in vivo cell engineering, and healthy aging are attracting growing attention from investors.
Tune in to hear Kevin’s perspective on the future of biotech investing and what it takes to turn breakthrough discoveries into transformative therapies.
Links:
Connect with Kevin White, PhD, and learn about the Boehringer Ingelheim Venture Fund.
Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.
Learn about the Tulane Center of Excellence in Sex-Based Precision Medicine.
Register for the Fat Tuesday Reception at BIO 2026 and check out Elaine’s panel on Tuesday 6/23.
Connect with Ian McLachlan, BIO from the BAYOU producer.
Learn more about BIO from the BAYOU – the podcast.
Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.
